PRPH
Prophase Labs Inc
$
0.350
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.439899
Open
0.4382
VWAP
--
Vol
3.18M
Mkt Cap
14.55M
Low
0.3415
Amount
--
EV/EBITDA(TTM)
--
Total Shares
19.08M
EV
23.38M
EV/OCF(TTM)
--
P/S(TTM)
1.48
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
3.55M
+43.49%
--
--
5.69M
+80.86%
--
--
9.67M
+294.05%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for ProPhase Labs, Inc. (PRPH) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 0.66%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+0.66%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Prophase Labs Inc (PRPH.O) is 0.00, compared to its 5-year average forward P/E of -36.80. For a more detailed relative valuation and DCF analysis to assess Prophase Labs Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-36.80
Current PE
0.00
Overvalued PE
154.78
Undervalued PE
-228.38
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
1.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
23.62
Undervalued EV/EBITDA
-20.69
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
1.88
Current PS
0.73
Overvalued PS
3.14
Undervalued PS
0.62
Financials
Annual
Quarterly
FY2025Q1
YoY :
-39.26%
1.43M
Total Revenue
FY2025Q1
YoY :
-52.00%
-3.66M
Operating Profit
FY2025Q1
YoY :
-15.31%
-4.68M
Net Income after Tax
FY2025Q1
YoY :
-130.56%
0.11
EPS - Diluted
FY2025Q1
YoY :
+6.19%
-3.98M
Free Cash Flow
FY2025Q1
YoY :
-1541.57%
36.76
Gross Profit Margin - %
FY2025Q1
YoY :
+164.86%
-221.40
FCF Margin - %
FY2025Q1
YoY :
+39.42%
-326.90
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PRPH News & Events
Events Timeline
2025-07-23 (ET)
2025-07-23
08:03:25
ProPhase Labs announces closing of $3M senior secured convertible notes
2025-07-21 (ET)
2025-07-21
08:04:54
ProPhase Labs board approves crypto treasury initiative
2025-07-21
08:04:29
ProPhase board authorizes exploration of strategic reverse merger
Sign Up For More Events
Sign Up For More Events
News
1.0
07-29NewsfilterProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
8.5
07-23NewsfilterProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing
2.0
07-08BenzingaWhy ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
GXAI
Gaxos.ai Inc.
1.220
USD
-3.94%
EDUC
Educational Development Corp
1.370
USD
+2.24%
MDRR
Medalist Diversified Reit Inc
11.300
USD
+10.57%
TKLF
Tokyo Lifestyle Co Ltd
3.915
USD
-1.44%
DPRO
Draganfly Inc
4.590
USD
-12.40%
BOF
BranchOut Food Inc
2.600
USD
0.00%
AQMS
Aqua Metals Inc
0.443
USD
-12.28%
LOBO
LOBO EV Technologies Ltd
0.436
USD
-3.54%
PHGE
Biomx Inc
0.413
USD
-4.62%
FAQ
What is Prophase Labs Inc (PRPH) stock price today?
The current price of PRPH is 0.3503 USD — it has decreased -21.17 % in the last trading day.
What is Prophase Labs Inc (PRPH)'s business?
What is the price predicton of PRPH Stock?
What is Prophase Labs Inc (PRPH)'s revenue for the last quarter?
What is Prophase Labs Inc (PRPH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Prophase Labs Inc (PRPH)'s fundamentals?
How many employees does Prophase Labs Inc (PRPH). have?